Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polaprezinc is an orally bioavailable chelate composed of zinc and L-carnosine, primarily used as a gastric mucosal protective agent. It is approved in Japan for the treatment and prevention of gastric ulcers and gastritis. Polaprezinc exerts cytoprotective, antioxidant, anti-ulcer, and anti-inflammatory effects by increasing the expression of antioxidant enzymes (such as SOD-1/2, HO-1), inhibiting pro-inflammatory cytokines (including TNF-alpha and IL-6), upregulating growth factors (PDGF-B, VEGF, NGF), and stimulating heat shock proteins (HSP90/70/60/47/27/10). Its mechanism includes scavenging reactive oxygen species in the gastric mucosa to protect cells from oxidative damage while promoting tissue repair. Polaprezinc also inhibits nuclear factor-kappaB activity to reduce inflammation and has demonstrated efficacy in improving healing rates for peptic ulcers as well as potential benefits for oral mucositis associated with cancer therapy[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polaprezinc.